Experienced in Orchiectomy

Dr. Daniel R. Saltzstein

Urology | General Surgery
Urology San Antonio P A
18915 Meisner Dr, Urology San Antonio, 
San Antonio, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Experienced in Orchiectomy
Urology San Antonio P A
18915 Meisner Dr, Urology San Antonio, 
San Antonio, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Daniel Saltzstein is an Urologist and a General Surgeon in San Antonio, Texas. Dr. Saltzstein is rated as an Experienced provider by MediFind in Orchiectomy. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Non-Muscle Invasive Bladder Cancer, Ureteroscopy, and Orchiectomy. Dr. Saltzstein is currently accepting new patients.

His clinical research consists of co-authoring 34 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Orchiectomy.

Specialties
Urology
General Surgery
Licenses
Surgery in TX
Hospital Affiliations
Baptist Medical Center
Methodist Hospital Stone Oak
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community First Health Plans
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 18 Less Insurance Carriers -

Locations

UROLOGY SAN ANTONIO P A
18915 Meisner Dr, Urology San Antonio, San Antonio, TX 78258

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase II Clinical Study of Intravesical Ruvidar® in Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) Carcinoma In-Situ (CIS) or Patients Who Are Intolerant to BCG Therapy (Study II)
A Phase II Clinical Study of Intravesical Ruvidar® in Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) Carcinoma In-Situ (CIS) or Patients Who Are Intolerant to BCG Therapy (Study II)
Enrollment Status: Recruiting
Publish Date: September 16, 2025
Intervention Type: Combination product
Study Drug: TLD-1433
Study Phase: Phase 2
ROBUST III - Re-Establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease - A Randomized Control Trial
ROBUST III - Re-Establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease - A Randomized Control Trial
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Device
Study Phase: Not Applicable
A Phase 3 Study of Cretostimogene Grenadenorepvec in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG)
A Phase 3 Study of Cretostimogene Grenadenorepvec in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG)
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2025
Intervention Type: Other, Biological
Study Drugs: CG0070, N-Dodecyl-B-D-Maltoside
Study Phase: Phase 3
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Terminated
Publish Date: December 09, 2024
Intervention Type: Drug
Study Drugs: Tazemetostat, Abiraterone/prednisone, Enzalutamide
Study Phase: Phase 1/Phase 2
A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence
A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence
Enrollment Status: Active_not_recruiting
Publish Date: November 04, 2024
Intervention Type: Drug
Study Drug: UGN-102
Study Phase: Phase 3
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 1/2 Study of Participants With Biochemical Recurrence of Prostate Cancer
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 1/2 Study of Participants With Biochemical Recurrence of Prostate Cancer
Enrollment Status: Completed
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: 64Cu-SAR-bisPSMA
Study Phase: Phase 1/Phase 2
A Randomized, Controlled, Open-Label Study of the Efficacy, Durability, and Safety of UGN-102 With or Without TURBT in Patients With Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
A Randomized, Controlled, Open-Label Study of the Efficacy, Durability, and Safety of UGN-102 With or Without TURBT in Patients With Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
Enrollment Status: Terminated
Publish Date: June 06, 2024
Intervention Type: Drug, Procedure
Study Drug: Mitomycin C
Study Phase: Phase 3
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
Enrollment Status: Terminated
Publish Date: February 05, 2024
Intervention Type: Drug
Study Drugs: VERU-111, Enzalutamide, Abiraterone, Darolutamide and Apalutamide
Study Phase: Phase 3
Open-Label, Proof-of-Concept and Dose Finding Phase 1b/2 Study of VERU-100 in Men With Advanced Prostate Cancer
Open-Label, Proof-of-Concept and Dose Finding Phase 1b/2 Study of VERU-100 in Men With Advanced Prostate Cancer
Enrollment Status: Terminated
Publish Date: May 19, 2023
Intervention Type: Drug
Study Drug: VERU-100
Study Phase: Phase 1/Phase 2
The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma: A Multicenter, Prospective Blinded Pivotal Study
The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma: A Multicenter, Prospective Blinded Pivotal Study
Enrollment Status: Completed
Publish Date: May 04, 2021
Intervention Type: Device, Procedure
Study Phase: Not Applicable
Phase II Clinical Chemoprevention Trial of Weekly Erlotinib Before Bladder Cancer Surgery
Phase II Clinical Chemoprevention Trial of Weekly Erlotinib Before Bladder Cancer Surgery
Enrollment Status: Terminated
Publish Date: July 07, 2020
Intervention Type: Other, Procedure, Drug
Study Phase: Phase 2
A Phase IIA Exploratory, Randomized, Placebo-Controlled Trial of Pomegranate Fruit Extract/Pomx™ in Subjects With Clinically Localized Prostate Cancer Undergoing Active Surveillance
A Phase IIA Exploratory, Randomized, Placebo-Controlled Trial of Pomegranate Fruit Extract/Pomx™ in Subjects With Clinically Localized Prostate Cancer Undergoing Active Surveillance
Enrollment Status: Completed
Publish Date: February 05, 2020
Intervention Type: Other, Drug
Study Phase: Phase 2
A Randomized and Open-label Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of LY01005 Versus Goserelin Comparator (ZOLADEX®) Following a Single Administration in Patients With Prostate Cancer
A Randomized and Open-label Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of LY01005 Versus Goserelin Comparator (ZOLADEX®) Following a Single Administration in Patients With Prostate Cancer
Enrollment Status: Completed
Publish Date: January 07, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 12 Less Clinical Trials

34 Total Publications

Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer With UGN-102: Outcomes From the 5-Year Long-Term Extension Study of the Single-Arm, Phase 2b Optima II Study.
Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer With UGN-102: Outcomes From the 5-Year Long-Term Extension Study of the Single-Arm, Phase 2b Optima II Study.
Journal: Clinical genitourinary cancer
Published: April 23, 2025
Similar Doctors
Advanced in Orchiectomy
Dr. Pranav Sharma
Urology
Advanced in Orchiectomy
Dr. Pranav Sharma
Urology
3601 4th Street, Suite 3B100, 
Anchorage, TX 
 (40.3 miles away)
806-743-1810
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Pranav Sharma is an Urologist in Anchorage, Texas. Dr. Sharma is rated as a Distinguished provider by MediFind in Orchiectomy. His top areas of expertise are Penile Cancer, Bladder Cancer, Renal Cell Carcinoma (RCC), Orchiectomy, and Nephrectomy. Dr. Sharma is currently accepting new patients.

Experienced in Orchiectomy
Dr. Ian M. Thompson
Urology | General Surgery
Experienced in Orchiectomy
Dr. Ian M. Thompson
Urology | General Surgery
2833 Babcock Rd, Suite 212, 
San Antonio, TX 
 (9.8 miles away)
210-960-0081
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ian Thompson is an Urologist and a General Surgeon in San Antonio, Texas. Dr. Thompson is rated as a Distinguished provider by MediFind in Orchiectomy. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Enlarged Prostate (BPH), Prostatectomy, and Lymphadenectomy.

Experienced in Orchiectomy
Dr. Jessica T. Goetz
Urology
Experienced in Orchiectomy
Dr. Jessica T. Goetz
Urology

The University Of Texas Health Science Center At San Antonio

8300 Floyd Curl Dr, 
San Antonio, TX 
 (9.3 miles away)
210-450-9000
Languages Spoken:
English, Mandarin, Spanish
See accepted insurances
Accepting New Patients

Jessica Goetz is an Urologist in San Antonio, Texas. Dr. Goetz is rated as an Experienced provider by MediFind in Orchiectomy. Her top areas of expertise are Neurogenic Bladder, Hypospadias, Neurogenic Bowel, Myelomeningocele, and Orchiectomy. Dr. Goetz is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Saltzstein's expertise for a condition
ConditionClose
    View All 19 Distinguished Conditions
    View All 25 Advanced Conditions
    View All 45 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile